PRINTER'S NO. 1562
No. 1142 Session of 2007
INTRODUCED BY WAGNER, M. SMITH, DeWEESE, BELFANTI, BENNINGTON, CREIGHTON, CURRY, DePASQUALE, FABRIZIO, FRANKEL, FREEMAN, GERGELY, GIBBONS, HORNAMAN, KORTZ, KOTIK, KULA, LEACH, MAHONEY, MANN, MARKOSEK, McGEEHAN, McILHATTAN, SANTONI, SOLOBAY, WALKO, J. WHITE, YOUNGBLOOD, YUDICHAK AND McILVAINE SMITH, MAY 18, 2007
REFERRED TO COMMITTEE ON HEALTH AND HUMAN SERVICES, MAY 18, 2007
AN ACT 1 Amending the act of June 26, 2001 (P.L.755, No.77), entitled "An 2 act establishing a special fund and account for money 3 received by the Commonwealth from the Master Settlement 4 Agreement with tobacco manufacturers; providing for home and 5 community-based care, for tobacco use prevention and 6 cessation efforts, for Commonwealth universal research 7 enhancement, for hospital uncompensated care, for health 8 investment insurance, for medical assistance for workers with 9 disabilities, for regional biotechnology research centers, 10 for the HealthLink Program, for community-based health care 11 assistance programs, for PACE reinstatement and PACENET 12 expansion, for medical education loan assistance and for 13 percentage allocation and appropriation of moneys," further 14 providing for definitions, for investment of fund and 15 accounts, for use of Tobacco Settlement Fund, for health 16 research program, for department responsibilities, for 17 National Institutes of Health funding formula and for 18 regional biotechnology research centers; establishing the 19 Jonas Salk Legacy Fund Program, the Jonas Salk Legacy Fund 20 Board and the Jonas Salk Legacy Fund; and providing for the 21 sale or assignment of Commonwealth Universal Research 22 Enhancement Program receipts and for the issuance of 23 Commonwealth Universal Research Enhancement Program bond. 24 The General Assembly of the Commonwealth of Pennsylvania 25 hereby enacts as follows: 26 Section 1. Sections 302, 303, 305 and 306 of the act of June
1 26, 2001 (P.L.755, No.77), known as the Tobacco Settlement Act, 2 are amended to read: 3 Section 302. Definitions. 4 The following words and phrases when used in this chapter 5 shall have the meanings given to them in this section unless the 6 context clearly indicates otherwise: 7 "Accounts." The Health Endowment Account for Long-Term Hope 8 established in section 303(b) [and], the Health Venture 9 Investment Account established in section 303(c) and the 10 Biotechnology Commercialization Account established in section 11 303(d). 12 "Bioscience product." As defined in section 1702. 13 "Board." The Tobacco Settlement Investment Board established 14 in section 304(a). 15 "Commercialization activity." Any activity that assists a 16 for-profit or not-for-profit bioscience institution or 17 organization in the jurisdiction of a regional biotechnology 18 research center in the testing, production and licensing or sale 19 of a bioscience product or leads to the testing, access or 20 creation of markets for the production, licensing or sale of a 21 bioscience product. The term includes, but is not limited to, 22 legal and business consulting services and expenses, assessing 23 the patentability of bioscience products, obtaining patent 24 protection for such bioscience products in the United States and 25 internationally, testing and marketing activities for bioscience 26 products and negotiating licensing or commercialization 27 agreements with licensees as well as development of new 28 technology transfer programs. 29 "Department." The Department of Community and Economic 30 Development of the Commonwealth. 20070H1142B1562 - 2 -
1 Section 303. Establishment of special fund and [account] 2 accounts. 3 (a) Tobacco Settlement Fund.--There is hereby established a 4 special fund known as the Tobacco Settlement Fund. Except as 5 provided in subsection (b), all payments received by the 6 Commonwealth pursuant to the Master Settlement Agreement shall 7 be deposited by the Treasury Department in the [fund] Tobacco 8 Settlement Fund. 9 (b) Health Account.--There is hereby established within the 10 [fund] Tobacco Settlement Fund the Health Endowment Account for 11 Long-Term Hope. [The] Except as provided in the act of April 9, 12 1929 (P.L.343, No.176), known as The Fiscal Code, the following 13 amounts shall be deposited by the Treasury Department into the 14 account: 15 (1) The jurisdictional payment received by the 16 Commonwealth pursuant to the Master Settlement Agreement. 17 (2) The strategic contribution payments received by the 18 Commonwealth pursuant to the Master Settlement Agreement. 19 (3) Earnings derived from the investment of the money in 20 the [fund] Tobacco Settlement Fund after deduction of 21 investment expenses, including such earnings as may have 22 accrued prior to the effective date of this chapter. 23 (4) Earnings derived from the investment of the money in 24 the Health Account after deduction of investment expenses and 25 the approved expenses of the board. 26 [(5) Money received as a result of investments from the 27 Health Venture Investment Account.] 28 (c) Health Venture Investment Account.--There is hereby 29 established within the [fund] Tobacco Settlement Fund the Health 30 Venture Investment Account. All proceeds received as a result of 20070H1142B1562 - 3 -
1 investments from the Health Venture Investment Account shall be 2 deposited into the Health Venture Investment Account. 3 (d) Biotechnology Commercialization Account.--There is 4 hereby established within the Tobacco Settlement Fund the 5 Biotechnology Commercialization Account. All proceeds received 6 as a result of investments from the Biotechnology 7 Commercialization Account shall be deposited into the 8 Biotechnology Commercialization Account. 9 Section 305. Investment of fund and accounts. 10 (a) Control and management.--Notwithstanding any other 11 provision of law, the board shall have exclusive control and 12 authority to manage, invest and reinvest money in the fund and 13 the Health Account in accordance with this section, subject, 14 however, to the exercise of that degree of judgment, skill and 15 care under the circumstances then prevailing that persons of 16 prudence, discretion and intelligence, who are familiar with 17 investment matters, exercise in the management of their own 18 affairs, not in regard to speculation but in regard to permanent 19 disposition of the funds, considering the probable income to be 20 derived from the investments and the probable safety of their 21 capital. The board may hold, purchase, sell, lend, assign, 22 transfer or dispose of any securities and investments, including 23 equity securities, in which money in the fund or the accounts 24 has been invested and of the proceeds of the investments, 25 including any directed commissions that have accrued to the 26 benefit of the fund or the accounts as a consequence of the 27 investments, and of money belonging to the fund or the accounts 28 subject to the standard of prudence in this section. 29 (b) Fiduciary status of board.--The members of the board and 30 their professional personnel shall stand in a fiduciary 20070H1142B1562 - 4 -
1 relationship to the Commonwealth and its citizens regarding the 2 investments of the money of the fund and the accounts and shall 3 not profit, either directly or indirectly, with respect thereto. 4 (c) Custodian.--The State Treasurer shall be the custodian 5 of the fund and the accounts. All investment draws from the fund 6 or the accounts shall be made by the State Treasurer in 7 accordance with requisitions signed by the secretary of the 8 board and ratified by resolution of the board. 9 (d) Authorized investment vehicles for the fund and the 10 Health Account.--The board may invest the money in the fund and 11 the Health Account in investments that meet the standard of 12 prudence set forth in subsection (a) by acquiring any type of 13 interest in a business organization existing under the laws of 14 any jurisdiction. The liability of the fund or the Health 15 Account shall be limited to the amount of their investment under 16 this subsection. 17 (e) Additional authorized investment vehicles for the Health 18 Account.--The board in its prudent discretion may invest the 19 money in the Health Account in venture capital investments, 20 private placement investments or other alternative investments 21 of any kind, structure or manner which meet the standard of 22 prudence set forth in subsection (a). The liability of the 23 Health Account shall be limited to the amount of its investment 24 under this subsection. 25 (f) Authorized investment vehicles for the Health Venture 26 Investment Account.--The board may invest the money in the 27 Health Venture Investment Account in investments which meet the 28 standard of prudence set forth in subsection (a) by becoming a 29 limited partner in partnerships that make venture capital 30 investments by acquiring equity interests or a combination of 20070H1142B1562 - 5 -
1 debt and equity interests in health care, biotechnology or any 2 other health-related businesses that are expected to grow 3 substantially in the future and in which the expected returns on 4 investment are to come predominantly from increases in value of 5 the equity interests and are not interests in or secured by real 6 estate. The board may invest in one or more limited partnerships 7 or comparable investment entities provided that the investment 8 guidelines and strategies of each investment entity require, in 9 the board's prudent discretion, that at least 70% of the 10 investments will be made in companies located primarily in 11 Pennsylvania or in companies willing to relocate significant 12 business operations to Pennsylvania. The liability of the fund 13 or the Health Venture Investment Account shall be limited to the 14 amount of its investment under this section. 15 (g) Requirements for venture capital investments.--The 16 [following are the] board, in its prudent discretion, may 17 establish reasonable requirements to participate in a venture 18 capital investment program undertaken by the board under 19 subsection (e) or (f). These requirements may, in the board's 20 discretion, include the following: 21 (1) Each general partner must: 22 (i) contribute 2% of the aggregate committee capital 23 as a general partner; and 24 (ii) subordinate 5% of the board's contribution in 25 terms of the distribution schedule, putting the general 26 partner in a first loss position with respect to the 27 board. 28 (2) The partnership must provide a preferred return of 29 no less than 5% to all limited partners. 30 (3) The partnership must agree to operate under a 20070H1142B1562 - 6 -
1 prudent expert standard of care. The board shall adopt 2 policies regarding cancellation of a contract with a general 3 partner based on poor performance which may include policies 4 relating to multiple instances of indemnification or 5 substantial changes in principals. 6 (4) The board must be given a seat on any limited 7 partner advisory/valuation committee. 8 (5) The board must be reimbursed for expenses for 9 attending limited partner advisory/valuation committee 10 meetings and partnership annual meetings. 11 (6) The partnership must issue to the board audited 12 financial statements on the basis of Generally Accepted 13 Accounting Principles. 14 (g.1) Authorized investment for Biotechnology 15 Commercialization Account.--The board may invest the money in 16 the Biotechnology Commercialization Account in investments in or 17 grants to the regional biotechnology research centers 18 established under Chapter 17 to support commercialization 19 activities in the respective region of each center that meet the 20 standard of prudence set forth in subsection (a). 21 (h) Legislative declaration.--The General Assembly finds and 22 declares that authorized investments of the fund or the accounts 23 made by or on behalf of the board under this section whereby the 24 board becomes a joint owner, limited partner or stockholder in a 25 company, corporation, limited partnership, association or other 26 lawful business organization are outside the scope of the 27 original intent of and do not violate the prohibition set forth 28 in section 8 of Article VIII of the Constitution of 29 Pennsylvania. 30 Section 306. Use of Tobacco Settlement Fund. 20070H1142B1562 - 7 -
1 (a) Annual report.--The Governor shall report on the fund in 2 the annual budget which shall include the amounts appropriated 3 to each program. 4 (b) Appropriations.-- 5 (1) [The] Except as provided in the act of April 9, 1929 6 (P.L.343, No.176), known as The Fiscal Code, the General 7 Assembly hereby appropriates funds in the fund in accordance 8 with the following percentages based on actual funds received 9 in each year or upon receipt of the final annual payment: 10 (i) Eight percent for deposit into the Health 11 Account pursuant to this chapter, which shall be 12 deposited immediately upon receipt. 13 (ii) Thirteen percent for home and community-based 14 services pursuant to Chapter 5. For fiscal year 2001- 15 2002, up to $13.5 million may be used for expanded 16 counseling, area agency on aging training and education, 17 assistive technology and for reducing waiting lists for 18 services in the Department of Aging. 19 (iii) Twelve percent for tobacco use prevention and 20 cessation programs pursuant to Chapter 7. 21 (iv) Eighteen percent for health and related 22 research pursuant to section 906 and one percent for 23 health and related research pursuant to section 909. 24 (v) Ten percent for the uncompensated care payment 25 program pursuant to Chapter 11. 26 (vi) Thirty percent for health investment insurance 27 pursuant to Chapter 13 and for the purchase of Medicaid 28 benefits for workers with disabilities pursuant to 29 Chapter 15. 30 (vii) [Eight] Four percent for the expansion of the 20070H1142B1562 - 8 -
1 PACENET program pursuant to Chapter 23. 2 (viii) Two percent for deposit into the Health 3 Venture Investment Account pursuant to this chapter. 4 (ix) Two percent for deposit into the Biotechnology 5 Commercialization Account pursuant to this chapter for 6 commercialization activities. 7 (2) In addition, any Federal funds received for any of 8 these programs is hereby specifically appropriated to those 9 programs. 10 (c) Lapses.--Lapses shall be deposited in the Health Account 11 except for the following: 12 (1) Lapses from moneys provided for the home and 13 community-based care services shall be reallocated to the 14 home and community-based care program for use in succeeding 15 years. 16 (2) Lapses from moneys provided for the health 17 investment insurance program shall be reallocated to the 18 health investment insurance program for use in succeeding 19 years. 20 (3) Lapses from moneys provided for the health venture 21 investment program shall be reallocated to the Health Venture 22 Investment Account for use in succeeding years. 23 (4) Lapses from moneys provided for commercialization 24 activities shall be reallocated to the Biotechnology 25 Commercialization Account for use in succeeding years. 26 Section 2. Section 902 of the act is amended by adding a 27 definition to read: 28 Section 902. Definitions. 29 The following words and phrases when used in this chapter 30 shall have the meanings given to them in this section unless the 20070H1142B1562 - 9 -
1 context clearly indicates otherwise: 2 * * * 3 "Direct research grant." A grant to conduct research that is 4 awarded by the National Institutes of Health, excluding all 5 contracts, cooperative agreements and those grants that are not 6 for investigator-initiated research projects ("R01" grants). 7 * * * 8 Section 3. Sections 903(b)(5), 904(3) and 908 of the act are 9 amended to read: 10 Section 903. Health research program. 11 * * * 12 (b) Advisory committee.-- 13 * * * 14 (5) The committee shall meet as needed, but at least 15 [twice] once a year, to fulfill the purposes provided for in 16 this chapter. A majority of the members of the committee 17 constitutes a quorum. A majority of the members of the 18 committee has authority to act upon any matter properly 19 before it. The committee is authorized to establish rules for 20 its operation and shall hold public hearings, as necessary, 21 to obtain public input and make recommendations to the 22 department regarding research priorities, evaluation and 23 accountability procedures and related issues. Meetings of the 24 committee shall be conducted under 65 Pa.C.S. Ch. 7 (relating 25 to open meetings). 26 * * * 27 Section 904. Department responsibilities. 28 The department has the following powers and duties: 29 * * * 30 (3) Except as provided in section 905(f) and (g), review 20070H1142B1562 - 10 -
1 applications and award research grants to applicants 2 consistent with the priorities established under paragraph 3 (2). Research grants may be awarded for a period not to 4 exceed [four] five years for each project. 5 * * * 6 Section 908. National Institutes of Health funding formula. 7 (a) Eligibility.--An institution that conducts research in 8 this Commonwealth and has received funding from the National 9 Institutes of Health during each of the three [immediately 10 preceding] most recent Federal fiscal years for which finalized 11 data is available from the National Institutes of Health as of 12 June 30 of the State fiscal year prior to the State fiscal year 13 in which the grant is awarded shall be eligible to receive a 14 grant pursuant to section 906(1). For one year from the 15 effective date of this act, an institution that has immediately 16 succeeded, by asset acquisition, the research function of 17 another institution that received National Institutes of Health 18 funding during any of the four immediately preceding fiscal 19 years shall be considered eligible to receive a grant pursuant 20 to section 906(1). 21 (b) Fund distribution.--Funds under this section shall be 22 distributed to eligible institutions as follows: 23 (1) Twenty percent shall be distributed to each 24 institution that receives more than $175,000,000 as an 25 average amount from the National Institutes of Health during 26 each of the three [immediately preceding] most recent Federal 27 fiscal years[.] for which finalized data is available from 28 the National Institutes of Health as of June 30 of the State 29 fiscal year prior to the State fiscal year in which the grant 30 is awarded. 20070H1142B1562 - 11 -
1 (2) Seventeen percent shall be distributed to each 2 institution that receives more than $175,000,000 in federally 3 sponsored research and development obligations in the 4 [immediately available preceding] most recent Federal fiscal 5 year [as reported by] for which finalized data is available 6 from the National Science Foundation and receives more than 7 [$60,000,000] $50,000,000 in direct research grant funding as 8 an average amount from the National Institutes of Health 9 during [the three immediately preceding] each of the three 10 most recent Federal fiscal years[.] for which finalized data 11 is available as of June 30 of the State fiscal year prior to 12 the State fiscal year in which the grant is awarded. 13 (3) The remaining funds shall be distributed to eligible 14 institutions based on the percentage calculated by dividing 15 an institution's average direct research grant award from the 16 National Institutes of Health for [the three immediately 17 preceding] each of the three most recent Federal fiscal years 18 for which finalized data is available as of June 30 of the 19 State fiscal year prior to the State fiscal year in which the 20 grant is awarded by the sum of the average annual direct 21 research grant funding award from the National Institutes of 22 Health for all Pennsylvania-based eligible institutions 23 during the three [immediately available preceding] most 24 recent Federal fiscal years[.] for which finalized data is 25 available as of June 30 of the State fiscal year prior to the 26 State fiscal year in which the grant is awarded. 27 (4) An institution is not eligible to receive funds 28 under more than one paragraph of this subsection. 29 (5) No funds shall be given to an institution that 30 qualifies for a grant of less than $25,000 under this 20070H1142B1562 - 12 -
1 section. The amount of funding that would have been 2 distributed to such an institution shall be redistributed 3 proportionally to institutions that are eligible under 4 subsection(b)(3). 5 (c) Additional requirements.--An institution that receives 6 $400,000 or more pursuant to this section shall include the 7 following information with its application under section 907(a): 8 (1) A plan for the timely licensure or commercial 9 development of research results conducted under this section, 10 including its management of intellectual property. 11 (2) Standard forms of agreement developed by the 12 institution for use in the licensing of research results. 13 (3) A plan to establish affiliations, exchanges, 14 partnerships or other cooperative efforts with postsecondary 15 educational institutions to provide programs to train 16 students and health professionals in the biomedical field. 17 (4) A description of the training opportunities provided 18 for researchers employed by the institution relating to the 19 licensing and commercial development of research. 20 (5) Outreach efforts directed toward informing 21 businesses and business organizations regarding recent 22 developments in research being conducted by the institutions. 23 (6) A plan for collaboration with an applicant, an 24 institution, a regional biomedical research center under 25 Chapter 17 or a for-profit corporation or other business 26 entity to participate in the development of research. 27 Section 4. Section 1702 of the act is amended by adding a 28 definition to read: 29 Section 1702. Definitions. 30 The following words and phrases when used in this chapter 20070H1142B1562 - 13 -
1 shall have the meanings given to them in this section unless the 2 context clearly indicates otherwise: 3 * * * 4 "Bioscience product." A therapeutic agent, diagnostic 5 biomedical device, process or service related to human health 6 that is developed or marketed by a for-profit or not-for-profit 7 institution or organization that is in the jurisdiction of a 8 regional biotechnology research center established under section 9 1703. 10 * * * 11 Section 5. Section 1703(a) and (j) of the act are amended 12 and the section is amended by adding a subsection to read: 13 Section 1703. Regional biotechnology research centers. 14 (a) Establishment of centers.--The department, in 15 consultation with the Department of Health, shall establish 16 three regional biotechnology research centers to facilitate 17 research and commercialization activity through the sharing of 18 funds and infrastructure. 19 * * * 20 (i.1) Application for commercialization activities.--Each 21 regional biotechnology research center created under this 22 section, acting with the approval of its board of directors, 23 shall annually submit an application to the department 24 requesting funding for commercialization activities in its 25 respective region. The application shall be based on a five-year 26 funding strategy. The application shall include the proposed 27 amount of money requested, the types of commercialization 28 activities to be funded, the process for identifying the 29 commercialization activities to be funded and the investment 30 vehicle or vehicles to support the commercialization activities, 20070H1142B1562 - 14 -
1 which shall include a proposed return to the Health Account as 2 contemplated by subsection (g)(3). The department may request 3 any other information deemed necessary related to the 4 application by a regional biotechnology research center. Prior 5 to the conclusion of the fifth year of each five-year funding 6 strategy, the regional biotechnology research center shall 7 develop a new five-year funding strategy on which its next five 8 annual applications will be based. 9 (j) Review and report.-- 10 (1) Each regional biotechnology research center shall be 11 subject to an annual performance review by the department. 12 The department may request other materials or information 13 from a regional biotechnology research center at such other 14 frequency or interval that the department deems appropriate. 15 (2) Each regional biotechnology research center shall, 16 by November 30, 2002, and annually thereafter, prepare and 17 submit a report to the department, the Department of Health, 18 the chair and minority chair of the Appropriations Committee 19 of the Senate, the chair and minority chair of the 20 Appropriations Committee of the House of Representatives, the 21 chair and minority chair of the Community and Economic 22 Development Committee of the Senate and the chair and 23 minority chair of the Commerce and Economic Development 24 Committee of the House of Representatives. This report shall 25 be in a form and manner developed by the department working 26 in cooperation with the Department of Health and shall 27 include the following: 28 (i) The current members of the board of directors 29 for the research center. 30 (ii) A description of the research facilities, 20070H1142B1562 - 15 -
1 including space and equipment. 2 (iii) The research center's current policies for the 3 management and development of intellectual property and 4 ownership of inventions and products created during the 5 course of research conducted through the center. 6 (iv) The research center's policies on conflicts of 7 interest and the handling of confidential material. 8 (v) A listing of all organizations and for-profit 9 and nonprofit institutions utilizing the services of the 10 research center during the prior year. 11 (vi) A listing of any licenses or other contractual 12 obligations in effect or anticipated for the intellectual 13 property developed at the research center during the 14 prior year. 15 (vii) A listing of any inventions, any patent 16 applications or patents issued, any products or other 17 intellectual property developed as a result of research 18 conducted through the research center during the prior 19 year. 20 (viii) A copy of the annual operating budget for the 21 year, with a listing of the sources of all funds, 22 including financial and in-kind services, personnel, 23 equipment or other material donations and contributions 24 by all parties involved in the research center; grants 25 obtained by or through the research center; Federal funds 26 leveraged and expenditures made, including infrastructure 27 expenditures; and administrative and staffing costs. 28 (ix) Information relating to commercialization 29 activities including: 30 (A) A list of commercialization activities 20070H1142B1562 - 16 -
1 supported by a research center in the prior year to 2 enter or develop markets for inventions, patents 3 issued, products or other intellectual property. 4 (B) The amount of moneys expended by each for- 5 profit and not-for-profit institution and 6 organization in the preceding year on 7 commercialization activities supported by a research 8 center and the amount of any return on investment to 9 the research center from those activities. 10 (C) The amount of moneys each for-profit and 11 not-for-profit institution and organization projects 12 to spend on commercialization activities supported by 13 a research center in the current year and the return 14 on investment to the research center projected from 15 that activity. 16 (D) The name of any organization within or 17 outside this Commonwealth that has committed funding 18 to a for-profit and not-for-profit institution and 19 organization in the current year for 20 commercialization activities supported by a research 21 center and the type and amount of that funding. 22 (E) A list of potential markets for the 23 bioscience product supported by a research center and 24 any and all target populations that could benefit 25 from the commercialization activity. 26 (F) Any other information deemed necessary by 27 the department related to commercialization 28 activities supported by a research center. 29 Section 6. The act is amended by adding a chapter to read: 30 CHAPTER 29 20070H1142B1562 - 17 -
1 BIOSCIENCE RESEARCH DEVELOPMENT 2 Section 2901. Definitions. 3 The following words and phrases when used in this chapter 4 shall have the meanings given to them in this section unless the 5 context clearly indicates otherwise: 6 "Advisory review panel." A panel of physicians, scientists 7 and researchers engaged by the Jonas Salk Legacy Fund Board 8 under section 2903. 9 "Bioscience industry." Research and development of 10 technology, therapies and treatments relative to human health, 11 medical and life science, including medical devices, chemical 12 and biological pharmaceuticals and the biological or 13 technological delivery of such materials. 14 "Board." The Jonas Salk Legacy Fund Board established under 15 section 2903. 16 "Bonds." Bonds, notes, instruments, refunding notes and 17 other evidences of indebtedness or obligations that the 18 Pennsylvania Economic Development Financing Authority is 19 authorized to issue pursuant to this chapter. 20 "CURE." The Commonwealth Universal Research Enhancement 21 Program established under section 903. 22 "CURE participant." A recipient of funds under section 908 23 or 909 in the fiscal year immediately preceding the effective 24 date of this chapter. 25 "CURE receipts." Up to one-half of the funds required to be 26 distributed for health and related research under section 27 306(b)(1)(iv). 28 "CURE receipts bonds." Limited obligation revenue bonds 29 issued by the Pennsylvania Economic Development Financing 30 Authority pursuant to section 2906. 20070H1142B1562 - 18 -
1 "Department." The Department of Community and Economic 2 Development of the Commonwealth. 3 "DOH." The Department of Health of the Commonwealth. 4 "Donor-directed funds." Contributions made to the Jonas Salk 5 Legacy Fund on which a donor has placed specific use conditions. 6 "Donor funds." Contributions made to the Jonas Salk Legacy 7 Fund on which no specific use conditions have been placed by the 8 donor. 9 "Economic Development Financing Law." The act of August 23, 10 1967 (P.L.251, No.102), known as the Economic Development 11 Financing Law. 12 "Financing authority." The Pennsylvania Economic Development 13 Financing Authority established under the act of August 23, 1967 14 (P.L.251, No.102), known as the Economic Development Financing 15 Law. 16 "Fund." The Jonas Salk Legacy Fund established under section 17 2904. 18 "Incubator." A facility in which small units of space are 19 leased by new companies in the bioscience industry and in which 20 management of the facility maintains or provides access to 21 business development services for use by all companies leasing 22 space in the facility. 23 "Infrastructure project." An activity designed to expand, 24 remodel, renovate, alter or construct biomedical research 25 laboratories including biology, biochemistry, cell biology, 26 microscopy, molecular biology, virology, immunology, physiology, 27 pathology and clinical research, including any of the following: 28 (1) Wet laboratories, including tissue culture 29 laboratories, anaerobic chambers, fermenters and laboratories 30 to conduct studies related to biochemistry, molecular 20070H1142B1562 - 19 -
1 biology, cell biology, pathology, organic chemistry and 2 physical chemistry. 3 (2) Dry laboratories, including the use of computers, 4 electronics and analytic equipment. 5 (3) Special function laboratories, including the use of 6 electrophysiology, biophysics, electron microscopes, confocal 7 microscopes, laser equipment, magnetic resonance imaging, 8 electron spin resonance spectroscopy, X-ray crystallography, 9 mass spectrometry, flow cytometry and robotic equipment. 10 (4) Clinical research centers. 11 (5) Incubator facilities to commercialize the 12 development of biomedical drugs and devices. 13 "MSA payments." Payments paid or to be paid to the 14 Commonwealth under the Master Settlement Agreement. 15 "Obligee of the financing authority" or "obligee." Any of 16 the following: 17 (1) A holder or owner of CURE receipts bonds. 18 (2) A trustee or other fiduciary for any holder or owner 19 of CURE receipts bonds. 20 (3) A provider of a letter of credit, policy of 21 municipal bond insurance or other credit enhancement or 22 liquidity facility or an agreement for interest rate 23 management for CURE receipts bonds. 24 "Opt out date." The date set by the Jonas Salk Legacy Fund 25 Board for the receipt of notice from CURE participants that they 26 do not desire to participate in the program established in this 27 chapter. 28 "Project." An infrastructure project or a starter kit 29 project, as the context may require. 30 "Program." The Jonas Salk Legacy Fund Program established 20070H1142B1562 - 20 -
1 under section 2902. 2 "Public health research." Research concerning the protection 3 and improvement of the health of populations that: 4 (1) Builds the evidence base to guide policymaking for 5 public health practice. 6 (2) Seeks to apply research studies to health practice 7 needs. 8 (3) Translates health research in a manner to facilitate 9 its application to policy, financial and organizational 10 issues that concern the delivery of health care and social 11 services. 12 (4) Produces new insights and innovative solutions to 13 community health problems. 14 (5) Addresses an important public health need, is 15 relevant to reducing health disparities and has the potential 16 for broad impact across more than one subject area. 17 "Starter kit project." An activity to renovate, furnish and 18 equip research facilities, including the acquisition of 19 equipment and advanced instrumentation, to assist in attracting 20 highly rated research faculty to the applicant. 21 Section 2902. Jonas Salk Legacy Fund Program. 22 (a) Establishment.--There is established a program to be 23 known as the Jonas Salk Legacy Fund Program. The program shall 24 provide grants to eligible applicants for projects and for the 25 purposes set forth in section 2904(b). The board shall develop 26 eligibility criteria for applicants and projects, including 27 permitted project costs, priorities in the consideration of 28 applications and guidelines for the implementation of the 29 program, including the payment of application fees. The board 30 shall insure the funds are used to support basic and applied 20070H1142B1562 - 21 -
1 research and economic development focused on improved health. 2 The department shall submit for publication in the Pennsylvania 3 Bulletin a notice of the date that the board will begin 4 accepting grant applications. 5 (b) Advisory review panels.-- 6 (1) An advisory review panel shall be engaged by the 7 board with respect to each proposal received. Its members 8 shall be individuals who are nationally recognized 9 physicians, scientists or researchers from the same or 10 similar discipline as the project proposal under review and 11 shall not be Pennsylvania residents. A member of an advisory 12 review panel shall not have a relationship, employment or 13 otherwise, with an applicant whose project is under review by 14 the panel. 15 (2) Members of an advisory review panel shall review a 16 project proposal upon receiving it from the board. The review 17 shall be conducted in a manner that recognizes scientific and 18 technical merit and commercialization potential, on the basis 19 of scientific need, scientific method, research design, 20 adequacy of facility and qualifications of the research 21 personnel. The advisory review panel shall provide its review 22 and recommendations to the board, and the board shall 23 consider the recommendations when making a funding 24 determination. The board shall place heavier weight or 25 emphasis on an advisory review panel's recommendations 26 regarding a starter kit project than those regarding an 27 infrastructure project. 28 (c) Starter kit project.-- 29 (1) A CURE participant or its affiliated medical center 30 located in this Commonwealth may submit an application to the 20070H1142B1562 - 22 -
1 board requesting a grant for a starter kit project. The 2 application shall be on a form required by the board and 3 shall include or demonstrate all of the following: 4 (i) The applicant's name and address. 5 (ii) The location of the project. 6 (iii) A description of the project. 7 (iv) A detailed description of proposed expenditures 8 for the project. 9 (v) A detailed description of other sources of 10 financing for the project, including the match required 11 under subsection (g). 12 (vi) A detailed statement by the applicant of the 13 reasons why the project will be beneficial to the 14 bioscience industry. 15 (vii) Any other information required by the board. 16 (2) Upon determining that an application is complete, 17 the board shall forward the application to the advisory 18 review panel engaged by the board for review of the 19 feasibility of the project. The board shall also review the 20 application and shall consider the advisory review panel's 21 recommendations as required by subsection (b). Upon being 22 satisfied that all requirements for awarding a grant to the 23 applicant have been met, the board may approve the 24 application and, if approved, the board shall award the grant 25 and shall notify the applicant of such approval. 26 (d) Infrastructure projects.-- 27 (1) A CURE participant or its affiliated medical center 28 located in this Commonwealth may submit an application to the 29 board requesting a grant for an infrastructure project. The 30 application shall be on a form required by the board and 20070H1142B1562 - 23 -
1 shall include or demonstrate all of the following: 2 (i) The applicant's name and address. 3 (ii) The location of the project. 4 (iii) A description of the project. 5 (iv) A detailed description of proposed expenditures 6 for the project. 7 (v) A detailed description of other sources of 8 financing for the project, including the match required 9 by subsection (g). 10 (vi) A detailed statement by the applicant of the 11 reasons why the project will be beneficial to the 12 bioscience industry. 13 (vii) Any other information required by the board. 14 (2) Upon determining that an application is complete, 15 the board shall forward the application to the advisory 16 review panel engaged by the board for review of the 17 feasibility of the project. The board shall also review the 18 application and shall consider the advisory review panel's 19 recommendations as required under subsection (b). Upon being 20 satisfied that all requirements for awarding a grant to the 21 applicant have been met, the board may approve the 22 application, and, if approved, the board shall award the 23 grant and shall notify the applicant of such approval. 24 (e) Donor funds.--Donor funds shall be transferred by the 25 department to the DOH for use in funding the types of grants 26 authorized under section 906(2) and (3) or for other public 27 health research programs. 28 (f) Donor-directed funds.--Donor-directed funds shall be 29 used, to the extent allowed by the direction, to enhance 30 existing Commonwealth programs, including the program 20070H1142B1562 - 24 -
1 established under this chapter. Donor-directed funds that are 2 required to be used for public health programs shall be 3 transferred to the DOH to be used as directed. 4 (g) Limitations.-- 5 (1) A grant awarded for an infrastructure project or a 6 starter kit project shall not exceed 50% of the estimated 7 cost of the project as approved by the board. The balance of 8 the cost of the project shall be funded by the applicant from 9 other non-State public and private sources. Moneys derived 10 from non-State public and private sources that are used to 11 recruit or retain faculty by an eligible applicant may be 12 counted toward the match required by this paragraph. 13 (2) Subject to section 2903(l), interest earned on money 14 in the fund shall be transferred by the department to the DOH 15 to award grants for the public health research programs in 16 accordance with guidelines established by the DOH and 17 submitted annually for publication in the Pennsylvania 18 Bulletin. 19 (3) Except as provided in subsection (h), CURE 20 participants are not eligible to receive grants under the 21 program, and recipients of grants under the program are not 22 eligible for funding under CURE. 23 (h) Special provisions relating to CURE and CURE 24 participants.-- 25 (1) A CURE participant shall be enrolled in the program 26 unless the CURE participant provides written notice to the 27 board by the opt out date that it does not desire to 28 participate in the program. If a CURE participant enrolled in 29 the program desires to apply for a grant under this chapter, 30 it shall apply and be approved as provided in this chapter. 20070H1142B1562 - 25 -
1 CURE participants enrolled in the program shall also continue 2 to be eligible to receive funding under CURE through June 30, 3 2012, at the same level provided in section 908 or 909, as 4 applicable, as if none of the CURE receipts had been sold or 5 assigned under section 2905. The board shall have the 6 authority to use moneys in the fund to supplement moneys 7 available under section 908 or 909 for CURE in order to 8 continue to provide funding at this level through June 30, 9 2012. A CURE participant may use National Institutes of 10 Health funds as a match against moneys in the fund used to 11 supplement moneys available under this act for CURE in order 12 to continue to provide funding at this level through June 30, 13 2012. This commitment shall not apply to any reduction in 14 funding under CURE that occurs for reasons unrelated to the 15 sale or assignment of CURE receipts authorized under section 16 2905. After June 30, 2012, CURE participants enrolled in the 17 program shall continue to be eligible to receive funding 18 under CURE at the level then available under section 908 or 19 909. 20 (2) CURE participants that opt out of the program 21 pursuant to paragraph (1) shall continue to be eligible to 22 receive funding under CURE at the same level provided in 23 section 908 or 909, as applicable, as if none of the CURE 24 receipts had been sold or assigned pursuant to section 2905. 25 This commitment shall not apply to any reduction in funding 26 under CURE that occurs for reasons unrelated to the sale or 27 assignment of CURE receipts under section 2905. 28 (3) Notwithstanding any provision of law to the 29 contrary, the DOH is authorized to reduce the amount of a 30 grant to be awarded under CURE to a CURE participant who is 20070H1142B1562 - 26 -
1 enrolled in the program to the extent of the amount of any 2 moneys in the fund used by the board under paragraph (1) to 3 supplement moneys available under CURE for such grant. In 4 such event, the grant agreement entered into by the DOH and 5 the CURE participant will govern the use of that portion of 6 the grant being funded by MSA payments through sections 908 7 and 909 and administered by the DOH. A separate grant 8 agreement shall be entered into by the board and the CURE 9 participant to govern the use of that portion of the grant 10 being funded by the board pursuant to paragraph (1). 11 (4) Notwithstanding any provision of law to the 12 contrary, the DOH is authorized to reduce the amount 13 available for distribution under section 906(2) and (3) to an 14 aggregate of the greater of 28.5% of all funds available to 15 the DOH under section 906 following the sale or assignment of 16 CURE receipts under section 2905 or $10,000,000, provided 17 however, that the $10,000,000 minimum amount shall be subject 18 to reduction in the event the amount of funds available to 19 the DOH under section 906 is reduced for reasons unrelated to 20 the sale or assignment of CURE receipts as authorized under 21 section 2905. 22 (5) Notwithstanding any provision of law to the 23 contrary, moneys received by the DOH for CURE in a fiscal 24 year may be retained by the DOH for up to an additional 25 fiscal year in order to complete the award process for a 26 particular recipient or recipients for the fiscal year in 27 which the moneys were received. The DOH may not reassign the 28 moneys to other recipients. 29 (i) Evaluation criteria relating to diversification.--In 30 reviewing applications for grants under the program, the board 20070H1142B1562 - 27 -
1 shall evaluate the use and development of disadvantaged 2 businesses as defined in 62 Pa.C.S. § 2102 (relating to 3 definitions). The board shall develop criteria that evaluates 4 the applicant's commitment and plan to provide fair and 5 representative opportunities for disadvantaged businesses in its 6 projects and in contracts relating to its projects as well as 7 the applicant's commitment and plan to employ in the project a 8 diverse professional and scientific work force, including 9 minorities and women. In those cases where the board has cause 10 to believe that an applicant receiving a grant under this 11 chapter has failed to comply with the provisions of the 12 applicant's plan, the applicant shall be subject to sanctions. 13 The sanctions may include: 14 (1) Declaring the applicant ineligible to receive future 15 grants. 16 (2) Suspending the applicant from receiving grants for a 17 set period of time. 18 (3) Requiring repayment of a portion of the grant 19 awarded to the applicant. 20 (j) Reports.--An applicant receiving a grant under this 21 chapter shall report annually to the board on the progress of 22 the project or as often as the board deems necessary. 23 Section 2903. Jonas Salk Legacy Fund Board. 24 (a) Establishment.--There is hereby established in the 25 department the Jonas Salk Legacy Fund Board. The board shall 26 consist of the following members: 27 (1) The Secretary of Community and Economic Development 28 or his designee, who shall be chair of the board. 29 (2) The Secretary of Health or his designee, who shall 30 be secretary of the board. 20070H1142B1562 - 28 -
1 (3) One individual appointed by each of the following: 2 the President pro tempore of the Senate, the Minority Leader 3 of the Senate, the Speaker of the House of Representatives 4 and the Minority Leader of the House of Representatives, all 5 of whom shall have professionally relevant experience and 6 none of whom may be members of the General Assembly or staff 7 of members of the General Assembly. 8 (4) Seven individuals appointed by the Governor, one of 9 whom shall be a real estate development professional, four of 10 whom shall be from the biotechnology or biomedical community, 11 one of whom shall be a commercialization professional and one 12 of whom shall be a member of the Jonas Salk family or a Jonas 13 Salk family-designated representative, in either case with 14 respect to the latter member, chosen from a list of at least 15 three people provided by the Jonas Salk family to the 16 Governor. 17 (5) Four individuals appointed by the Governor, all of 18 whom shall be representatives of an academic medical center, 19 a college or a university located in this Commonwealth. These 20 members shall be nonvoting. 21 (b) Compensation.--Members of the board shall serve without 22 compensation but shall be reimbursed for actual and reasonable 23 expenses incurred in the performance of their official duties. 24 (c) Organization.--The members shall select from among 25 themselves such officers in addition to a chairperson and 26 secretary as they shall determine. 27 (d) Terms.--Members shall serve a term of two years from the 28 date of their appointment and until their respective successors 29 are duly appointed and qualified. Members shall be eligible for 30 reappointment. 20070H1142B1562 - 29 -
1 (e) Meetings.--The board shall meet at the call of the 2 chairperson. 3 (f) Quorum and vote.--Seven voting members of the board 4 shall constitute a quorum. The consent of at least a majority of 5 the voting members of the board in attendance at a meeting with 6 a quorum shall be necessary for the board to take action. 7 (g) Fiduciary relationship.--The members of the board shall 8 stand in a fiduciary relationship with the Commonwealth as to 9 the moneys in the fund and investments of the board. 10 (h) Liability.--Members of the board shall not be liable 11 personally on any obligations of the financing authority, 12 including the bonds of the financing authority. 13 (i) Conflict of interest.--The board shall establish 14 conflict of interest policies and procedures to which members 15 shall adhere. 16 (j) Initial appointment and vacancy.--Appointing authorities 17 shall appoint initial members to the board within 30 days of the 18 effective date of this chapter. Whenever a vacancy occurs on the 19 board, the appointing authority shall appoint a successor member 20 within 30 days of the vacancy. 21 (k) Records and meetings.--The board shall keep a record of 22 its proceedings which shall be open to inspection by the public. 23 Meetings of the board shall be conducted under 65 Pa.C.S. Ch. 7 24 (relating to open meetings). 25 (l) Staff and legal representation.--The department shall 26 provide administrative staff to the board and shall provide the 27 board with legal representation. The board shall reimburse, from 28 interest earned on moneys in the fund, the department for the 29 cost of providing these services to the board. 30 (m) Powers.--The board shall have the power and may do any 20070H1142B1562 - 30 -
1 appropriate act necessary or convenient to carry out and 2 effectuate the purposes of this chapter. The board shall also 3 have the following powers and authority: 4 (1) To enter into contracts with investment advisors, 5 fund managers and other consultants and advisors as the board 6 deems necessary to efficiently and competently carry out the 7 provisions of this chapter. 8 (2) To solicit and accept funds from all sources. 9 (3) To form independent advisory boards and panels. 10 (4) To manage, invest and reinvest money in the fund 11 subject to the exercise of that degree of judgment, skill and 12 care under the circumstances then prevailing that persons of 13 prudence, discretion and intelligence who are familiar with 14 investment matters exercise in the management of their own 15 affairs, not in regard to speculation but in regard to 16 permanent disposition of the funds, considering the probable 17 income to be derived from the investments and the probable 18 safety of their capital. 19 (5) To hold, purchase, sell, lend, assign, transfer or 20 dispose of any securities and investments, including equity 21 securities, in which money in the fund or the accounts has 22 been invested, the proceeds of the investments, including any 23 directed commissions that have accrued to the benefit of the 24 fund as a consequence of the investments, and money belonging 25 to the fund subject to the standard of prudence in this 26 section. 27 Section 2904. Jonas Salk Legacy Fund. 28 (a) Establishment.--A special fund is hereby established 29 within the State Treasury to be known as the Jonas Salk Legacy 30 Fund. The following shall be deposited into the fund: 20070H1142B1562 - 31 -
1 (1) Proceeds of the sale or assignment of the CURE 2 receipts to the financing authority received by the 3 Commonwealth. 4 (2) Federal funds. 5 (3) Private funds, including funds from foundations, 6 donor funds and donor-directed funds, contributed to the 7 fund. 8 (4) Moneys contributed to the fund by Commonwealth 9 agencies. 10 (5) Any other moneys appropriated by the General 11 Assembly to the fund. 12 (6) Interest earned on moneys in the fund. 13 (b) Use of funds.--Moneys in the fund shall be used for the 14 grants to be awarded under the program, for the purposes set 15 forth in this chapter to pay reasonable fees to investment 16 advisors or fund managers engaged by the board pursuant to 17 section 2903 and to pay the expenses of the board in the 18 administration of the program. Moneys in the fund are hereby 19 appropriated, upon approval of the Governor, for the purposes 20 set forth in this chapter. 21 Section 2905. Sale or assignment of CURE receipts. 22 (a) Sale or assignment.--The Commonwealth is authorized, 23 with the approval of the Governor, to sell absolutely or assign 24 irrevocably, in whole or in part, to the financing authority the 25 Commonwealth's right, title and interest in and to the MSA 26 payments to the extent of the amount of the CURE receipts. 27 References in this section to the CURE receipts shall be deemed 28 to refer to the MSA payments to the extent of the amount of the 29 CURE receipts. In order to effectuate the sale or assignment, 30 the Commonwealth shall have the authority to do all of the 20070H1142B1562 - 32 -
1 following: 2 (1) Execute sales or irrevocable assignments of all or a 3 portion of the Commonwealth's right, title and interest in 4 and to the MSA payments to the extent of the amount of the 5 CURE receipts. If sales are utilized, each sale shall be 6 deemed a true sale of property and shall be evidenced by a 7 purchase and sale agreement and such other documentation as 8 the financing authority deems necessary or desirable. 9 (2) Effectuate the sale or assignment without regard to 10 existing laws governing other property sales or financial 11 transactions by the Commonwealth. 12 (3) Enter into covenants with the financing authority 13 regarding the use of proceeds of the sale or assignment so as 14 to protect continuing tax exemption on the financing 15 authority's tax-exempt bonds, if applicable. 16 (4) Exercise such powers in accordance with such terms 17 and conditions and documentation as the financing authority 18 deems necessary or desirable. 19 (b) Deposit of proceeds.--Proceeds received by the 20 Commonwealth from the sale or assignment of CURE receipts shall 21 be deposited into the fund. 22 (c) Payments to financing authority.--Notwithstanding any 23 provision of law to the contrary, if the Commonwealth sells or 24 assigns, in whole or in part, to the financing authority the 25 Commonwealth's right, title and interest in and to the CURE 26 receipts, then to the extent of the CURE receipts sold or 27 assigned, all moneys that otherwise would be required to be paid 28 to the DOH for CURE under section 306, and all rights to receive 29 those payments whether now existing or hereafter coming into 30 existence, shall be paid directly by the State Treasurer to the 20070H1142B1562 - 33 -
1 financing authority or its trustee immediately upon receipt by 2 the Commonwealth, deposited into a trust fund established by the 3 financing authority and pledged to pay the CURE receipts bonds 4 until all CURE receipts bonds, together with the interest on 5 those bonds, and all obligations of the financing authority 6 relating to the CURE receipts bonds are fully paid or provided 7 for. The authority of the State Treasurer to make payments to 8 the financing authority as provided in this subsection shall 9 constitute a continuing appropriation, and funds to be paid 10 pursuant to this subsection shall not lapse. All CURE receipts 11 sold or assigned to the financing authority at all times shall 12 be property of the financing authority and shall not be property 13 of the Commonwealth. 14 (d) Bankruptcy.--The financing authority shall not have the 15 right to commence a bankruptcy case under 11 U.S.C. Ch. 9 16 (relating to adjustment of debts of a municipality) so long as 17 any CURE bonds are outstanding. 18 Section 2906. CURE receipt bonds. 19 (a) Authorization.--The financing authority may issue CURE 20 receipts bonds in the manner provided in this chapter and in the 21 Economic Development Financing Law for the issuance of financing 22 authority indebtedness. In connection with the issuance of CURE 23 receipts bonds, and in order to secure the payment of the CURE 24 receipts bonds, the financing authority, in addition to its 25 other powers set forth in this chapter, shall have all powers 26 granted to it in this chapter and under the Economic Development 27 Financing Law. 28 (b) Taxability.--CURE receipts bonds may be taxable or tax- 29 exempt bonds. 30 (c) Use of proceeds.--The proceeds of an issue of CURE 20070H1142B1562 - 34 -
1 receipts bonds shall be used to pay the purchase price for the 2 CURE receipts; to fund any required reserves, including debt 3 service reserves; to capitalize interest; and to pay costs of 4 issuance, including, but not limited to, costs of obtaining 5 credit enhancement for the CURE receipts bonds. 6 (d) Maturity.--CURE receipts bonds shall mature at such time 7 or times not exceeding 40 years from their respective dates of 8 original issue as the financing authority shall by resolution 9 determine. 10 (e) Sale.--CURE receipts bonds may be sold at public sale, 11 invited sale or private sale for the price or prices the 12 financing authority determines. 13 (f) Negotiable instruments.--CURE receipts bonds shall have 14 the qualities of negotiable instruments under 13 Pa.C.S. 15 (relating to commercial code). 16 (g) Refunding.--Subject to the provisions of this chapter 17 and the terms of CURE receipts bonds issued in accordance with 18 this chapter, the financing authority may refund any outstanding 19 CURE receipts bonds whether the debt represents principal or 20 interest, in whole or in part, at any time. For the purposes of 21 this subsection, the term "refund" and its variations means the 22 issuance and sale of obligations the proceeds of which are used 23 or are to be used for the payment or redemption of outstanding 24 obligations upon or prior to maturity. 25 (h) Interest rate management.--With respect to bonds, the 26 financing authority may negotiate and enter into interest rate 27 exchange agreements, interest rate cap agreements, collar 28 agreements, corridor agreements, ceiling agreements, floor 29 agreements, forward agreements, float agreements and other 30 similar agreements, which, in the judgment of the financing 20070H1142B1562 - 35 -
1 authority, will assist the financing authority in managing the 2 interest costs of the financing authority. 3 (i) No debt or liability of Commonwealth.-- 4 (1) CURE receipts bonds issued under this chapter shall 5 not be a debt or liability of the Commonwealth or any 6 political subdivision and shall not create or constitute any 7 indebtedness, liability or obligation of the Commonwealth or 8 any political subdivision, legal, moral or otherwise. 9 (2) CURE receipts bonds shall be payable solely from the 10 following: 11 (i) The proceeds of CURE receipts bonds. 12 (ii) The CURE receipts sold or assigned to the 13 financing authority. 14 (3) All CURE receipts bonds shall contain on their faces 15 a statement to the effect that: 16 (i) The financing authority is obligated to pay the 17 principal of or the interest on the CURE receipts bonds 18 only from its revenues, receipts or funds pledged or 19 available for their payment as authorized in this 20 chapter. 21 (ii) Neither the Commonwealth nor any political 22 subdivision is obligated to pay the principal or 23 interest. 24 (iii) Neither the faith and credit nor the taxing 25 power of the Commonwealth or any political subdivision is 26 pledged to the payment of the principal of or the 27 interest on the CURE receipts bonds. 28 (j) Nonliability.--No financing authority board member, 29 employee of the financing authority or person executing the CURE 30 receipts bonds shall be liable personally on any CURE receipts 20070H1142B1562 - 36 -
1 bonds by reason of their issuance. CURE receipts bonds shall 2 contain a statement of the limitation set forth in this 3 subsection. 4 (k) CURE receipts bonds deemed valid.--Any CURE receipts 5 bond reciting in substance that it has been issued by the 6 financing authority to accomplish the public purposes of this 7 chapter shall be conclusively deemed in any suit, action or 8 proceeding involving the validity or enforceability of the CURE 9 receipts bonds or security for the bonds to have been issued for 10 such purpose. 11 (l) Notice and challenges.-- 12 (1) The financing authority shall file a copy of any 13 resolution authorizing the issuance of CURE receipts bonds 14 adopted by it for public inspection in its office and in the 15 office of the secretary of the department, and shall publish 16 in the Pennsylvania Bulletin a notice stating the fact and 17 date of the adoption, the places where the resolution has 18 been so filed for public inspection, the date of publication 19 of the notice and that any action or proceeding of any kind 20 or nature in any court questioning the validity or proper 21 authorization of CURE receipts bonds provided for by the 22 resolution, or the validity of any covenants, agreements or 23 contract provided for by such resolution, shall be commenced 24 within ten days after the publication of the notice. 25 (2) Upon publication of notice in the Pennsylvania 26 Bulletin and if no action or proceeding questioning the 27 validity or proper authorization of CURE receipts bonds or 28 the validity of any covenants, agreements or contracts 29 provided for by the resolution shall be commenced within ten 30 days after the publication of the notice in the Pennsylvania 20070H1142B1562 - 37 -
1 Bulletin, then all residents, taxpayers and all other persons 2 forever shall be barred and foreclosed from instituting or 3 commencing any action or proceeding in any court or pleading 4 any defense to any action or proceedings, questioning the 5 validity or proper authorization of such CURE receipts bonds 6 or the validity of the covenants, agreements or contracts, 7 and the CURE receipts bonds, covenants, agreements and 8 contracts shall be conclusively deemed to be valid and 9 binding obligations in accordance with their terms and tenor. 10 (3) After the issuance of CURE receipts bonds, all CURE 11 receipts bonds shall be conclusively presumed to be fully 12 authorized and issued by all the laws of this Commonwealth, 13 and any person shall be estopped from questioning their sale, 14 execution or delivery by the financing authority. 15 (m) Contracts with obligees of financing authority.--Except 16 as otherwise provided in any resolution of the financing 17 authority authorizing or awarding CURE receipt bonds, the terms 18 of the CURE receipts bonds and of this chapter in effect when 19 the CURE receipts bonds were authorized shall constitute a 20 contract between the financing authority and obligees of the 21 financing authority, subject to modification in such manner as 22 the resolution, the trust indenture securing the CURE receipts 23 bonds or the CURE receipts bonds shall provide. 24 (n) Commonwealth pledge; limitation of powers.-- 25 (1) The Commonwealth pledges to and agrees with each 26 obligee of the financing authority that the Commonwealth will 27 not limit or alter the rights and powers vested in the 28 financing authority or otherwise created by this chapter in 29 any manner inconsistent with the obligations of the financing 30 authority to its obligees until all CURE receipts bonds at 20070H1142B1562 - 38 -
1 any time issued, together with the interest on the CURE 2 receipts bonds, are fully paid and discharged. 3 (2) If and to the extent that the Commonwealth sells or 4 assigns CURE receipts pursuant to section 2905, the 5 Commonwealth pledges to and agrees with each obligee of the 6 financing authority that the Commonwealth will not abolish or 7 reduce the financing authority's rights to receive amounts 8 set forth in section 2905(c), including, but not limited to, 9 abolishing or reducing the amounts required to be transferred 10 to the DOH under section 306. 11 (o) CURE receipts bonds to be legal investments.-- 12 (1) CURE receipts bonds issued pursuant to this chapter 13 are securities in which all of the following may properly and 14 legally invest funds, including capital, deposits or other 15 funds in their control or belonging to them: 16 (i) Government agencies. 17 (ii) Insurance companies. 18 (iii) Trust companies. 19 (iv) Banking associations, banking corporations and 20 savings banks. 21 (v) Investment companies. 22 (vi) Executors, trustees and other fiduciaries. 23 (vii) Trustees of any retirement, pension or annuity 24 fund or system of the Commonwealth. 25 (2) CURE receipts bonds issued by the financing 26 authority are securities that may properly and legally be 27 deposited with and received by a government agency for any 28 purpose for which the deposit of bonds or other obligations 29 of the Commonwealth are authorized by law. 30 (p) Additional rights.--An obligee of the financing 20070H1142B1562 - 39 -
1 authority shall have the right in addition to all other rights 2 that may be conferred on the obligee, subject only to any 3 contractual restrictions binding upon the obligee: 4 (1) By mandamus, suit, action or proceeding at law or in 5 equity, to compel the financing authority and the members, 6 officers, agents or employees of the financing authority to 7 perform each and every term, provision and covenant contained 8 in any bond or contract of the financing authority with or 9 for the benefit of the obligee and to require the carrying 10 out of any or all covenants and agreements of the financing 11 authority and the fulfillment of all duties imposed upon the 12 financing authority by this chapter. 13 (2) By proceeding in equity, to obtain an injunction 14 against any acts or things that may be unlawful or the 15 violation of any of the rights of the obligee of the 16 financing authority. 17 (3) To require the financing authority to account as if 18 it were the trustee of an express trust for the obligees of 19 the financing authority for any pledged revenues received. 20 (4) To enforce a pledge of or security interest in 21 revenues of the financing authority securing payment of the 22 CURE receipts bonds against all Commonwealth and local public 23 officials in possession of any revenues at any time, which 24 revenues may be collected directly from such officials upon 25 notice by the obligee of the financing authority or a trustee 26 for application to the payment of the CURE receipts bonds as 27 and when due for deposits in any sinking, bond or debt 28 service fund established with the trustee at the times and in 29 the amounts specified in the CURE receipts bonds or the 30 resolution or indenture or trust agreement securing the CURE 20070H1142B1562 - 40 -
1 receipts bonds. Any Commonwealth or local public official in 2 possession of any revenues shall make payment against receipt 3 and shall thereby be discharged from any further liability or 4 responsibility for the revenues. If the payment is to an 5 obligee of the financing authority, it shall be made against 6 surrender of the CURE receipts bonds to the payor for 7 delivery to the financing authority in the case of payment in 8 full, otherwise, it shall be made against production of the 9 CURE receipts bonds for notation on the bonds of the amount 10 of the payment. The provisions of this section with respect 11 to the enforceability and collection of revenues that secure 12 CURE receipts bonds of the financing authority shall 13 supersede any contrary or inconsistent statutory provision or 14 rule of law. 15 (5) This subsection shall be construed and applied to 16 fulfill the legislative purpose of clarifying and 17 facilitating the financing of the financing authority by 18 assuring to the obligees of the financing authority the full 19 and immediate benefit of the security for the financing 20 without delay, diminution or interference based on any 21 statute, decision, ordinance or administrative rule or 22 practice. 23 (q) Validity of pledge.--Any pledge or grant of a lien on or 24 security interest in CURE receipts made by the financing 25 authority shall be valid and binding from the time when the 26 pledge is made. The CURE receipts so pledged and thereafter 27 received by the financing authority shall immediately be subject 28 to the lien of any such pledge, lien or security interest 29 without any physical delivery of the CURE receipts or further 30 act. The lien of the pledge or security interest shall be valid 20070H1142B1562 - 41 -
1 and binding as against all parties having claims of any kind in 2 tort, contract or otherwise against the financing authority 3 irrespective of whether the parties have notice of any such 4 pledge. Neither the resolution nor any other instrument of the 5 financing authority by which a pledge, lien or security interest 6 is created need be recorded or filed to perfect such pledge or 7 security interest. 8 (r) Security interest in funds and accounts.--Any moneys 9 deposited in any fund created by the financing authority pledged 10 to be used to pay debt service on CURE receipts bonds of the 11 financing authority, including any sinking fund or debt service 12 reserve fund, and all investments and proceeds of investments 13 thereof, shall, without further action or filing, be subjected 14 to a perfected security interest for the obligees of the 15 financing authority with respect to the CURE receipts bonds 16 until such moneys or investments shall be disbursed in 17 accordance with this chapter and subject to the terms of any 18 trust indenture or other contract between the financing 19 authority and the obligees of the financing authority with 20 respect to the CURE receipts bonds. 21 (s) Exemption from State and local taxation.--The 22 effectuation of the purposes of the financing authority is for 23 the benefit of the people of this Commonwealth, for the increase 24 of commerce and prosperity and for the improvement of health, 25 safety, welfare and living conditions. CURE receipts bonds 26 issued by the financing authority, the transfer and the income 27 from the CURE receipts bonds, including profit made on their 28 sale, are free from State and local taxation within this 29 Commonwealth. This exclusion under this subsection shall not 30 extend to gift, estate, succession or inheritance taxes or any 20070H1142B1562 - 42 -
1 other taxes not levied directly on the CURE receipts bonds, 2 their transfer, the income from the CURE receipts bonds or the 3 realization of profits on their sale. 4 (t) Exemptions from Federal taxation.-- 5 (1) If the CURE receipts bonds issued by the financing 6 authority are tax-exempt bonds for which Federal law requires 7 a private activity volume cap allocation, the department may 8 issue an allocation upon receipt of a written request by the 9 financing authority. An allocation must be issued by the 10 department prior to the approval of the resolution 11 authorizing the issuance of the bonds by the financing 12 authority. 13 (2) If gubernatorial approval is required by Federal or 14 State law, the Governor may approve the issuance of the CURE 15 receipts bonds by the financing authority upon receipt of 16 written request for approval from the financing authority. 17 The written request must state all of the following: 18 (i) The financing authority has conducted a public 19 hearing, with appropriate public notice, concerning the 20 purposes for which the bonds are to be issued. 21 (ii) A description of the project or projects that 22 will benefit from the grants being funded by the bonds. 23 (iii) A description of the grant or grants awarded 24 for the project or projects. 25 (iv) A summary of the comments made and questions 26 posed at the public hearing. 27 (u) Rights and remedies of obligees.--The rights and 28 remedies conferred upon or granted to obligees of the financing 29 authority pursuant to this chapter shall be in addition to and 30 not in limitation of rights and remedies lawfully granted to 20070H1142B1562 - 43 -
1 obligees of the authority by resolution providing for the 2 issuance of bonds or by any trust agreement or another agreement 3 under which the CURE receipts bonds may be issued or secured. 4 Section 7. This act shall take effect immediately. C19L35AJM/20070H1142B1562 - 44 -